摘要
目的分析缺血性院内卒中(in-hospital stroke,IHS)患者溶栓治疗的疗效。方法收集近5年缺血性IHS患者临床资料,按是否接受重组组织型纤溶酶原激活剂(recombinant tissue plasminogen activato,r-tPA)溶栓治疗分为溶栓组和非溶栓组,比较两组出院时预后良好[改良Rankin量表评分(modified Rankin scale,mRS)0~2分]比例。结果本研究共收集缺血性IHS患者121例,其中溶栓组6例,非溶栓组115例。出院时预后良好(mRS 0~2分)患者溶栓组6例(占100%),而非溶栓组42例(占36.5%),溶栓组预后良好比例显著高于非溶栓组(P<0.05)。结论缺血性IHS患者r-tPA溶栓治疗可显著改善临床预后。
Objective To analyze the clinical effects of thrombolytic therapy in patients with ischemic in-hos- pital stroke (IHS). Methods The clinical data were collected from patients with ischemic IHS in the last five years. The patients were divided into thrombolysis group and non- thrombolysis group, according to the use of recombinant tissue plasminogen activator (r-tPA) treatment. The clinical outcomes were measured by the modified Rankin scale (mRS) at discharge. Results There were a total of 121 patients in this study. There were 6 patients in thrombolysis group and 115 patients in the non-thrombolysis group, respectively. Six patients (100%) in the thrombolysis group achieved favor- able outcomes (mRS 0 ~ 2) at discharge whereas only 42 patients (36.5%) in the non- thrombolysis group achieved fa- vourable outcomes. The rate of favorable outcomes was significantly higher in the thrombolysis group than in the non-thrombolysis group (P〈 0.05). Conclusions R-tPA thrombolytic therapy can improve the prognosis of patients with ischemic IHS.
出处
《中国神经精神疾病杂志》
CAS
CSCD
北大核心
2017年第1期4-7,共4页
Chinese Journal of Nervous and Mental Diseases
基金
国家自然科学基金(编号:81171084)
广东省自然科学基金(编号:2014A030313384)
广东省医学科研基金(编号:A2014381)
广州市科技计划(编号:2014Y2-00505
201508020004)
关键词
院内卒中
溶栓治疗
预后
In-hospital stroke Thrombolysis Prognosis